Literature DB >> 22945224

Differing approaches to experimental therapeutics: are we a world apart?

Timothy P Cripe.   

Abstract

Mesh：

Year:  2012        PMID： 22945224      PMCID： PMC3437590          DOI： 10.1038/mt.2012.174

Source DB:  PubMed          Journal:  Mol Ther        ISSN： 1525-0016            Impact factor:   11.454


× No keyword cloud information.
  2 in total

1.  Ad3-hTERT-E1A, a fully serotype 3 oncolytic adenovirus, in patients with chemotherapy refractory cancer.

Authors:  Otto Hemminki; Iulia Diaconu; Vincenzo Cerullo; Saila K Pesonen; Anna Kanerva; Timo Joensuu; Kalevi Kairemo; Leena Laasonen; Kaarina Partanen; Lotta Kangasniemi; Andre Lieber; Sari Pesonen; Akseli Hemminki
Journal:  Mol Ther       Date:  2012-08-07       Impact factor: 11.454

2.  Risks and benefits of phase 1 oncology trials, 1991 through 2002.

Authors:  Elizabeth Horstmann; Mary S McCabe; Louise Grochow; Seiichiro Yamamoto; Larry Rubinstein; Troy Budd; Dale Shoemaker; Ezekiel J Emanuel; Christine Grady
Journal:  N Engl J Med       Date:  2005-03-03       Impact factor: 91.245
  2 in total
  2 in total

1.  Treatment of chemotherapy-refractory cancer in the advanced therapy access program.

Authors:  Akseli Hemminki
Journal:  Mol Ther       Date:  2012-09       Impact factor: 11.454

2.  "Special exemptions": should they be put on trial?

Authors:  H Bobby Gaspar; Sue Swift; Adrian J Thrasher
Journal:  Mol Ther       Date:  2013-02       Impact factor: 11.454
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.